Rectal Cancer

  • Kyle Wang
  • Andrew Z. Wang
  • Joel E. Tepper


For locally advanced (e.g., T3 or N+) rectal cancer, RT is conventionally delivered with concurrent chemotherapy over a course of 5–6 weeks, 4–8 weeks before or after surgery. However, numerous randomized trials have utilized a “short course” technique, where RT is delivered in five fractions, without concurrent chemotherapy, and with surgery taking place within 1 week. In this section we will focus on the use of short course RT in the treatment of rectal cancer. In contrast to other gastrointestinal malignancies, SBRT does not have an established role in the treatment of rectal cancer; hypofractionation for rectal cancer is delivered to conventional large pelvic volumes usually with 3D-CRT.


Rectal cancer Short course Neoadjuvant Preoperative 


  1. 1.
    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–42.CrossRefPubMedGoogle Scholar
  3. 3.
    NCCN Rectal. Rectal Cancer (Version 2.2016). 2016. Accessed 18 Oct 2016.
  4. 4.
    Goodman KA, Patton CE, Fisher GA, et al. Appropriate customization of radiation therapy for stage II and III rectal cancer: executive summary of an ASTRO clinical practice statement using the RAND/UCLA appropriateness method. Pract Radiat Oncol. 2016;6(3):166–75.CrossRefPubMedGoogle Scholar
  5. 5.
    Myerson RJ, Tan B, Hunt S, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys. 2014;88(4):829–36.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206.CrossRefPubMedGoogle Scholar
  9. 9.
    Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Swedish Rectal Cancer Trial G. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23(34):8697–705.CrossRefPubMedGoogle Scholar
  10. 10.
    Ansari N, Solomon MJ, Fisher RJ, et al. Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). In: Ann Surg; 2016.Google Scholar
  11. 11.
    Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med. 1997;336(14):980–7.CrossRefGoogle Scholar
  12. 12.
    Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.CrossRefPubMedGoogle Scholar
  13. 13.
    Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811–20.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pettersson D, Lorinc E, Holm T, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg. 2015;102(8):972–8; discussion 978.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Kyle Wang
    • 1
  • Andrew Z. Wang
    • 1
  • Joel E. Tepper
    • 1
  1. 1.Department of Radiation OncologyUniversity of North Carolina HospitalsChapel HillUSA

Personalised recommendations